Fig. 3: Enhanced potency and breadth via co-expression and isotype modification of SC-PGT121 and SC-VRC07. | Nature Communications

Fig. 3: Enhanced potency and breadth via co-expression and isotype modification of SC-PGT121 and SC-VRC07.

From: Intravaginal delivery of mRNA-encoded antibodies with enhanced breadth and potency for SHIV/HIV protection

Fig. 3: Enhanced potency and breadth via co-expression and isotype modification of SC-PGT121 and SC-VRC07.

a Schematic of antibody co-expression. Two SC-mRNAs encoding different antibodies were co-transfected, resulting in the expression of a combined antibody (SC-aIgG #1 + 2) as well as the individual antibodies (SC-aIgG #1 and SC-aIgG #2) separately. Created in BioRender. Santangelo, P. (2025) https://BioRender.com/v81ivzo. b Representative immunostaining images of mRNA-expressed antibodies in A549 cells. The expression of PGT121, VRC07, and PGT121 + VRC07 (combinational treatment) with four different isotypes (anchored IgG, secreted IgA, anchored IgA, and IgM-tail) was visualized after staining with AF488-conjugated anti-human IgA or IgG antibodies. The scale bar represents 20 µm. c JESS Western blot analysis of SC-aIgG, SC-sIgA, and SC-IgM-tail variants of PGT121, VRC07, and PGT121 + VRC07. d, e TZM-bl neutralization assays against five SHIV and six HIV strains from different clades. f Summary of 50% inhibitory concentrations (IC50). All neutralization assays were performed in duplicate and independently repeated at least twice.

Back to article page